United Therapeutics Corp

Research United Therapeutics Corp (UTHR) on Bullrun: valuation model: 12.8% undervalued, market cap USD 23.13B, P/E 20.1. Explore financials, valuation history, model signals, and stock context.

Key Metrics

TickerUTHR
ExchangeNASDAQ
CountryUnited States
SectorHealthcare
IndustryDrug Manufacturers-Specialty & Generic
CurrencyUSD
Valuation signal12.8% undervalued
Market capUSD 23.13B
P/E20.1
Financial periodFY2025
RevenueUSD 3.18B
Revenue growth10.6%
Net incomeUSD 1.33B
Free cash flowUSD 1.04B
Gross margin87.9%

Valuation Snapshot

Bullrun's latest valuation model marks United Therapeutics Corp as 12.8% undervalued; latest market cap is USD 23.13B; P/E is 20.1.

About United Therapeutics Corp

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise;

Frequently asked questions

Is United Therapeutics Corp overvalued or undervalued?

Bullrun's valuation model currently marks United Therapeutics Corp as 12.8% undervalued.

What is United Therapeutics Corp's market cap?

United Therapeutics Corp's market capitalization is USD 23.13B.

What is United Therapeutics Corp's P/E ratio?

United Therapeutics Corp's price-to-earnings (P/E) ratio is 20.1.